Acinetobacter baumannii complex: Difference between revisions
From IDWiki
Acinetobacter baumannii complex
No edit summary |
m (Text replacement - "[[Cellular shape::" to "[[Shape::") |
||
| Line 4: | Line 4: | ||
*Contains ''Acinetobacter baumannii'', ''[[Acinetobacter nosocomialis]]'', and ''[[Acinetobacter pittii]]'' |
*Contains ''Acinetobacter baumannii'', ''[[Acinetobacter nosocomialis]]'', and ''[[Acinetobacter pittii]]'' |
||
*Non-motile, non-fermenting [[Stain::Gram-negative]] [[ |
*Non-motile, non-fermenting [[Stain::Gram-negative]] [[Shape::bacillus]] |
||
== Management == |
== Management == |
||
Revision as of 14:22, 8 October 2020
Background
Microbiology
- Contains Acinetobacter baumannii, Acinetobacter nosocomialis, and Acinetobacter pittii
- Non-motile, non-fermenting Gram-negative bacillus
Management
- Choice of antibiotic depends on susceptibility testing
- Possible options include:
- Cefepime, ceftriaxone, and cefotaxime
- Cefiderocol
- Carbapenems
- Tigecycline
- Colistin and polymyxin B (though Acinetobacter junii has inherent resistance)
- Aminoglycosides may not penetrate well into lungs and brain, so are usually avoided
- Bacteriophages are promising
References
- ^ Mical Paul, Elena Carrara, Pilar Retamar, Thomas Tängdén, Roni Bitterman, Robert A. Bonomo, Jan de Waele, George L. Daikos, Murat Akova, Stephan Harbarth, Celine Pulcini, José Garnacho-Montero, Katja Seme, Mario Tumbarello, Paul Christoffer Lindemann, Sumanth Gandra, Yunsong Yu, Matteo Bassetti, Johan W. Mouton, Evelina Tacconelli, Jesús Rodríguez-Baño. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection. 2022;28(4):521-547. doi:10.1016/j.cmi.2021.11.025.
